对抗体药物合物的PK生物分析,使用连接体结合测定挑战和生物分析策略
Xiaonan Liu1, Tao Xu1, Nan Zhang1
1Frontage Laboratories, Exton, PA, USA.
Bioanalysis
|August 19, 2025
概括
在药理动力学研究中,对抗体与药物合物 (ADCs) 进行表征至关重要的是联结试验 (LBAs). 为ADCs开发强大的LBA需要解决结构异质性等挑战,以确保准确的治疗评估.
科学领域:
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
- 分析化学 分析化学
背景情况:
- 抗体-药物合物 (ADC) 是用于瘤学和免疫学的先进生物治疗药物.
- 药理动力学 (PK) 特性对于ADC的有效性,安全性和性能至关重要.
- 配体结合试验 (LBA) 是生物分析的敏感,强大和成本效益高的方法.
研究的目的:
- 在ADC PK研究中审查LBAs的应用.
- 概述ADC生物分析中常见的方法挑战.
- 讨论开发ADC可靠的LBA方法的策略.
主要方法:
- 对ADC生物分析中LBA应用的文献综述.
- 识别ADC的LBA开发中存在的共同挑战.
- 讨论对测试验证的战略考虑.
主要成果:
- LBAs被广泛用于量化总抗体和ADC分析剂.
- ADC的结构异质性,分析物不稳定性和灵敏度要求构成了发展挑战.
- 战略测定开发对于准确可靠的生物分析测量至关重要.
结论:
- LBAs是ADC药理动力学特征的关键工具.
- 为了在ADC研究中成功开发LBA,必须克服特定的挑战.
- 本综述为ADC领域的LBA测定开发提供了强大的指导.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.7K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.1K
相关概念视频
Protein-Drug Binding: Determination Methods
302
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
302
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
274
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
274
The Equilibrium Binding Constant and Binding Strength
13.4K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.4K
